Clinical Trial

Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The prognosis of advanced breast cancer does not improve much recently although varies of adjuvant drugs have been tried.Dendritic cells co-cultured with cytokine-induced killer cells(DC-CIK) immunotherapy has been proved to improve survival in several cancers, but its role in advanced breast cancer stains unclear. The purpose of this study is to evaluate the efficacy and safety of DC-CIK immunotherapy combined with capecitabine versus capecitabine monotherapy for the treatment of advanced breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-07-07.
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-02-21
Trial Details
NCT Number NCT02491697
Lead Sponsor The First People's Hospital of Changzhou
Conditions Breast Cancer
Enrollment 400 participants
Start Date 2016-02
Primary Completion 2030-08 (estimated)
Study Completion 2033-08 (estimated)
Updated on ClinicalTrials.gov 2016-02-23